Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist
- PMID: 7883025
- DOI: 10.1016/0014-2999(94)90218-6
Tolerance to peripheral, but not central, effects of ropinirole, a selective dopamine D2-like receptor agonist
Abstract
Studies were conducted to determine possible development, and underlying mechanisms, of tolerance to the hypotensive effects of ropinirole (4-[2-(dipropylamino)ethyl]-1-3-dihydro-2H-indol-2-one HCl), a selective dopamine receptor agonist, following twice daily oral administration to cynomolgus monkeys and spontaneously hypertensive rats (SHR). Tolerance to the hypotensive effects of the compound developed in both species within one week of repeated dosing. Tolerance which developed in rats was dose-related and could not be attributed to altered plasma/drug concentrations or be overcome by increasing the i.v. challenge dose of ropinirole. Cross-tolerance was shown to the dopamine receptor agonist bromocriptine. Similar hypotensive responses to bethanidine were seen in rats treated with ropinirole or vehicle. Tolerance to hypolocomotor effects of the compound were not apparent in the same time frame. The dopamine D2 receptor antagonist, domperidone, caused hypertension in ropinirole-but not vehicle-treated rats. Results reported in this paper are not consistent with a down-regulation of peripheral dopamine D2-like receptors but suggest a compensatory increase in basal sympathetic tone.
Similar articles
-
Hypotensive action of bromocriptine in the DOCA-salt hypertensive rat: contribution of spinal dopamine receptors.Fundam Clin Pharmacol. 1998;12(6):599-606. doi: 10.1111/j.1472-8206.1998.tb00992.x. Fundam Clin Pharmacol. 1998. PMID: 9917201
-
Central bromocriptine-induced tachycardia is reversed to bradycardia in conscious, deoxycorticosterone acetate-salt hypertensive rats.Pharmacol Toxicol. 2001 May;88(5):238-43. Pharmacol Toxicol. 2001. PMID: 11393583
-
Interactions between domperidone and ropinirole, a novel dopamine D2-receptor agonist.Br J Clin Pharmacol. 1991 Oct;32(4):483-8. doi: 10.1111/j.1365-2125.1991.tb03935.x. Br J Clin Pharmacol. 1991. PMID: 1683559 Free PMC article. Clinical Trial.
-
Ropinirole: a dopamine agonist for the treatment of Parkinson's disease.Am J Health Syst Pharm. 1999 Feb 1;56(3):217-24. doi: 10.1093/ajhp/56.3.217. Am J Health Syst Pharm. 1999. PMID: 10030505 Review.
-
Dopamine receptors and hypertension. Physiologic and pharmacologic implications.Am J Med. 1984 Oct 5;77(4A):37-44. doi: 10.1016/s0002-9343(84)80036-4. Am J Med. 1984. PMID: 6148892 Review.
Cited by
-
A study of tolerance to apomorphine.Br J Pharmacol. 1996 Mar;117(5):781-6. doi: 10.1111/j.1476-5381.1996.tb15260.x. Br J Pharmacol. 1996. PMID: 8851490 Free PMC article.
-
Update on ropinirole in the treatment of Parkinson's disease.Neuropsychiatr Dis Treat. 2009;5:33-6. Epub 2009 Apr 8. Neuropsychiatr Dis Treat. 2009. PMID: 19557097 Free PMC article.
-
Ropinirole: a review of its use in the management of Parkinson's disease.Drugs. 2000 Jul;60(1):115-37. doi: 10.2165/00003495-200060010-00007. Drugs. 2000. PMID: 10929932 Review.
-
Dopamine D2 agonists, bromocriptine and quinpirole, increase MPP+ -induced toxicity in PC12 cells.Neurotox Res. 2006 Aug;10(1):31-42. doi: 10.1007/BF03033332. Neurotox Res. 2006. PMID: 17000468
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources